TargetMol

WAY-100635 Maleate

Product Code:
 
TAR-T2631
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2631-2mg2mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-5mg5mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-1mL1 mL * 10 mM (in DMSO)£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-25mg25mg£222.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-50mg50mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-100mg100mg£490.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2631-500mg500mg£1,010.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
WAY-100635 is a specific and effective 5-HT receptor antagonist (IC50=0.95 nM).
CAS:
1092679-51-0
Formula:
C29H38N4O6
Molecular Weight:
538.645
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9968
SMILES:
OC(=O)C=C/C(O)=O.COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1
Target:
Dopamine Receptor; 5-HT Receptor

References

1. Corradetti R, et al. J Pharmacol Exp Ther. 1996, 278(2), 679-688. 2. Fletcher A, et al. Behav Brain Res. 1996, 73(1-2), 337-353. 3. Hall H, et al. Brain Res. 1997, 745(1-2), 96-108. 4. Forster EA, et al. Eur J Pharmacol. 1995, 281(1), 81-88. 5. Laporte AM, et al. Eur J Pharmacol. 1994, 271(2-3), 505-514.